Fragility fractures in chronic kidney disease: An opinion-based approach

Cleveland Clinic Journal of Medicine

Volumn 76, Issue 12, 2009, Pages 715-723

  Miller, Paul D ^a  

^a UNIVERSITY OF COLORADO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER;

BLOOD; CHRONIC KIDNEY FAILURE; DIFFERENTIAL DIAGNOSIS; HUMAN; OSTEOPOROSIS; PATHOLOGIC FRACTURE; PATHOPHYSIOLOGY; RENAL OSTEODYSTROPHY; REVIEW;

BIOLOGICAL MARKERS; DIAGNOSIS, DIFFERENTIAL; FRACTURES, SPONTANEOUS; HUMANS; OSTEOPOROSIS; RENAL INSUFFICIENCY, CHRONIC; RENAL OSTEODYSTROPHY;

EID: 74049101459     PISSN: 08911150     EISSN: None     Source Type: Journal    
DOI: 10.3949/ccjm.76a.08108     Document Type: Review

References (68)

1. Melton LJ 3rd. Epidemiology worldwide. Endocrinol Metab Clin North Am 2003; 32:1-13.
2. Burge R, Dawson-Hughes B, Solomon DH, Wong JB, King A, Tosteson A. Incidence and economic burden of osteoporosis-related fractures in the United States, 2005-2025. J Bone Miner Res 2007; 22:465-475.
3. Barrett-Connor E, Siris ES, Wehren LE, et al. Osteoporosis and fracture risk in women of different ethnic groups. J Bone Miner Res 2005; 20:185-194.
4. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. Report of a WHO Study Group. World Health Organ Tech Rep Ser 1994; 843:1-129.
5. Miller PD, Bonnick SL. Clinical application of bone densitometry. In: Favus MJ, editor. Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism. 4th ed. American Society for Bone and Mineral Research. Philadelphia, PA: Lippincott Williams & Wilkins; 1999.
6. Nickolas TL, Leonard MB, Shane E. Chronic kidney disease and bone fracture: a growing concern. Kidney Int 2008; 74:721-731.
7. Gal-Moscovici A, Sprague SM. Osteoporosis and chronic kidney disease. Semin Dial 2007; 20:423-430.
8. National Kidney Foundation. Clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis 2003; 42(suppl 3):S1-S201.
9. Coresh J, Astor BC, Greene T, Eknoyan G, Levey AS. Prevalence of chronic kidney disease and decreased kidney function in the adult US population: Third National Health and Nutrition Examination Survey. Am J Kidney Dis 2003; 41:1-12.
10. Bennett WM. Reporting eGFR. Clin J Am Soc Nephrol 2008; 3:1561-1562.
11. Glassock RJ, Winearls C. Screening for CKD with eGFR: doubts and dangers. Clin J Am Soc Nephrol 2008; 3:1563-1568.
12. Parfitt AM, Drezner M, Glorieux F, et al. Bone histomorphometry: standardization of nomenclature, symbols, and units. Report of the ASBMR Histomorphometry Nomenclature Committee. J Bone Miner Res 1987; 2:595-610.
13. Andress DL, Sherrard DJ. The osteodystrophy of chronic renal failure. In: Schrier RW, editor: Diseases of the Kidney and Urinary Tract. Philadelphia, PA: Lippincott Williams & Wilkins; 2007:2431-2453.
14. Moe S, Drueke T, Cunningham J, et al. Definition, evaluation, and classification of renal osteodystrophy: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int 2006; 69:1945-1953.
15. NIH Consensus Development Panel Osteoporosis Prevention Diagnosis and Therapy. Osteoporosis prevention, diagnosis, and therapy. JAMA 2001; 285:785-795.
16. Baim S, Binkley N, Bilezikian JP, et al. Official positions of the International Society for Clinical Densitometry and executive summary of the 2007 ISCD Position Development Conference. J Clin Densitom 2008; 11:75-91.
17. Siris E, Miller P, Barrett-Connor E, et al. Identification and fracture outcomes of undiagnosed low bone mineral density in postmenopausal women: results from the National Osteoporosis Risk Assessment (NORA). JAMA 2001; 286:2815-2822.
18. Schuit SCE, Oei HH, Witteman JC, et al. Fracture incidence and association with bone mineral density in elderly men and women: the Rotterdam Study. Bone 2004; 34:195-202.
19. Bouxsein ML. Non-invasive measurements of bone strength: promise and peril. J Musculoskelet Neuronal Interact 2004; 4:404-405.
20. Seeman E. Bone quality: the material and structural basis of bone strength. J Bone Miner Metab 2008; 26:1-8.
21. Alem AM, Sherrard DJ, Gillen DL, et al. Increased risk of hip fracture among patients with end-stage renal disease. Kidney Int 2000; 58:396-399.
22. Ball AM, Gillen DL, Sherrard D, et al. Risk of hip fracture among dialysis and renal transplant recipients. JAMA 2002; 288:3014-3018.
23. Jadoul M, Albert JM, Akiba T, et al. Incidence and risk factors for hip or other bone fractures among hemodialysis patients in the Dialysis Outcomes and Practice Patterns Study. Kidney Int 2006; 70:1358-1366.
24. Stehman-Breen CO, Sherrard DJ, Alem AM, et al. Risk factors for hip fracture among patients with end-stage renal disease. Kidney Int 2000; 58:2200-2205.
25. Wehrli FW, Leonard MB, Saha PK, Gomberg BR. Quantitative high-resolution magnetic resonance imaging reveals structural implications of renal osteodystrophy on trabecular and cortical bone. J Magn Reson Imaging 2004; 20:83-89.
26. Genant HK, Lang TF, Engelke K, et al. Advances in the noninvasive assessment of bone density, quality, and structure. Calcif Tissue Int 1996; 59(suppl 1):S10-S15.
27. Roschger P, Paschalis EP, Fratzl P, Klaushofer K. Bone mineralization density distribution in health and disease. Bone 2008; 42:456-466.
28. Miller PD. Bone density and markers of bone turnover in predicting fracture risk and how changes in these measures predict fracture risk reduction. Curr Osteoporos Rep 2005; 3:103-110.
29. Miller PD, Hochberg MC, Wehren LE, Ross PD, Wasnich RD. How useful are measures of BMD and bone turnover? Curr Med Res Opin 2005; 21:545-554.
30. Chavassieux PM, Delmas PD. Bone remodeling: biochemical markers or bone biopsy? J Bone Miner Res 2006; 21:178-179.
31. Garnero P. Biomarkers for osteoporosis management: utility in diagnosis, fracture risk prediction and therapy monitoring. Mol Diagn Ther 2008; 12:157-170.
32. Hochberg M, Greenspan S, Wasnich R, Miller P, Thompson D, Ross P. Changes in bone density and turnover explain the reductions in incidence of nonvertebral fractures that occur during treatment with antiresorptive agents. J Clin Endocrinol Metab 2002; 87:1586-1592.
33. Bouxsein ML, Delmas PD. Considerations for development of surrogate endpoints for antifracture efficacy of new treatments in osteoporosis: a perspective. J Bone Miner Res 2008; 23:1155-1167.
34. Chen P, Satterwhite JH, Licatta AA, et al. Early changes in biochemical markers of bone formation predict BMD response to teriparatide in postmenopausal women with osteoporosis. J Bone Miner Res 2005; 20:962-970.
35. Miller PD, Delmas PD, Lindsay R, et al. Early responsiveness of women with osteoporosis to teriparatide after therapy with alendronate or risedronate. J Clin Endocrinol Metab 2008; 93:3785-3793.
36. Baim S, Miller PD. Assessing the clinical utility of serum CTX in postmenopausal osteoporosis and its use in predicting risk of osteonecrosis of the jaw. J Bone Miner Res 2009; 24:561-574.
37. Miller PD, Lerma EV. Renal bone diseases. In: Kleerekoper M, Siris E, McClung M, editors. The Bone and Mineral Manual-A Practical Guide. 2nd ed. Burlington, MA: Elsevier Academic Press; 2005:127-138.
38. Miller PD, Shane E. Management of transplantation renal bone disease: Interplay of bone mineral density and decisions regarding bisphosphonate use. In: Weir MR, editor. Medical Management of Kidney Transplantation. Philadelphia, PA: Lippincott Williams & Wilkins; 2004:359-375.
39. Levin A, Bakris GL, Molitch M, et al. Prevalence of abnormal serum vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney disease: results of the study to evaluate early kidney disease. Kidney int 2007; 71:31-38.
40. Vassalotti JA, Uribarri J, Chen SC, et al. Trends in mineral metabolism: Kidney Early Evaluation Program (KEEP) and the National Health and Nutrition Examination Survey (NHANES) 1999-2004. Am J Kidney Dis 2008; 51(suppl 2):S56-S68.
41. Meier C, Seibel MJ, Kraenzlin ME. Use of bone turnover markers in the real world: are we there yet? J Bone Miner Res 2009; 24:386-388.
42. Lehmann G, Ott U, Kaemmerer D, Schuetze J, Wolf G. Bone histomorphometry and biochemical markers of bone turnover in patients with chronic kidney disease stages 3-5. Clin Nephrol 2008; 70:296-305.
43. Miller PD. The role of bone biopsy in patients with chronic renal failure. Clin J Am Soc Nephrol 2008; 3(suppl 3):S140-S150.
44. Frost HM. Tetracycline-based histological analysis of bone remodeling. Calcif Tissue Res 1969; 3:211-237.
45. Hitt O, Jaworski ZF, Shimizu AG, Frost HM. Tissue-level bone formation rates in chronic renal failure, measured by means of tetracycline bone labeling. Can J Physiol Pharmacol 1970; 48:824-828.
46. Coen G. Adynamic bone disease: an update and overview. J Nephrol 2005; 18:117-122.
47. Parfitt AM. Renal bone disease: a new conceptual framework for the interpretation of bone histomorphometry. Curr Opin Nephrol Hypertens 2003; 12:387-403.
48. Brandenburg VM, Floege J. Adynamic bone diseaseùbone and beyond. NDT Plus 2008; 3:135-147. doi:10.1093/ndtplus/sfn040.
49. Hruska KA, Saab G, Mathew S, Lund R. Renal osteodystrophy, phosphate homeostasis, and vascular calcification. Semin Dial 2007; 20:309-315.
50. Toussaint ND, Elder GJ, Kerr PG. Bisphosphonates in chronic kidney disease; balancing potential benefits and adverse effects on bone and soft tissue. Clin J Am Soc Nephrol 2009; 4:221-233.
51. Miller PD. Is there a role for bisphosphonates in chronic kidney disease? Semin Dial 2007; 20:186-190.
52. Miller PD. Bisphosphonates: pharmacology and use in the treatment of osteoporosis. In: Marcus R, Feldman D, Nelson DA, Rosen CJ, editors. Osteoporosis. 3rd ed. Boston, MA: Elsevier Academic Press; 2008:1725-1736.
53. Russell RG, Watts NB, Ebetino FH, Rogers MJ. Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy. Osteoporosis Int 2008; 19:733-759.
54. Eisman JA, Civitelli R, Adami S, et al. Efficacy and tolerability of intravenous ibandronate injections in postmenopausal osteoporosis: 2-year results from the DIVA study. J Rheumatol 2008; 35:488-497.
55. Black DM, Delmas PD, Eastell RR, et al. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 2007; 356:1809-1822.
56. Lewiecki EM, Miller PD. Renal safety of intravenous bisphosphonates in the treatment of osteoporosis. Expert Opin Drug Saf 2007; 6:663-672.
57. Miller PD. Anti-resorptives in the management of osteoporosis. Best Pract Res Clin Endocrinol Metab 2008; 22:849-868.
58. Perazella MA, Markowitz GS. Bisphosphonate nephrotoxicity. Kidney Int 2008; 74:1385-1393.
59. Boonen S, Sellmeyer DE, Lippuner K, et al. Renal safety of annual zoledronic acid infusions in osteoporotic postmenopausal women. Kidney Int 2008; 74:641-648.
60. Neer RM, Arnaud CD, Zanchetta JR, et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 2001; 344:1434-1441.
61. Miller PD, Schwartz EN, Chen P, Misurski DA, Krege JH. Teriparatide in postmenopausal women with osteoporosis and mild or moderate renal impairment. Osteoporosis Int 2007; 18:59-68.
62. Miller PD, Roux C, Boonen S, Barton I, Dunlap L, Burgio D. Safety and efficacy of risedronate in patients with age-related reduced renal function as estimated by the Cockcroft and Gault method: a pooled analysis of nine clinical trials. J Bone Miner Res 2005; 20:2105-2115.
63. Jamal SA, Bauer DC, Ensrud KE, et al. Alendronate treatment in women with normal to severely impaired renal function: an analysis of the fracture intervention trial. J Bone Miner Res 2007; 22:503-508.
64. Ishani A, Blackwell T, Jamal SA, Cummings SR, Ensrud KE; MORE Investigators. The effect of raloxifene treatment in postmenopausal women with CKD. J Am Soc Nephrol 2008; 19:1430-1438.
65. Coco M, Glicklich D, Faugere MC, et al. Prevention of bone loss in renal transplant recipients: a prospective, randomized trial of intravenous pamidronate. J Am Soc Nephrol 2003; 14:2669-2676.
66. Palmer SC, McGregor DO, Strippoli GF. Interventions for preventing bone disease in kidney transplant recipients. Cochrane Database Syst Rev 2007; CD005015.
67. Ferreira MA. Diagnosis of renal osteodystrophy: when and how to use biochemical markers and non-invasive methods; when bone biopsy is needed. Nephrol Dial Transplant 2000; 15(suppl 5):8-14.
68. Trueba D, Sawaya BP, Mawad H, Malluche HH. Bone biopsy: indications, techniques, and complications. Semin Dial 2003; 16:341-345.